<DOC>
	<DOCNO>NCT01485003</DOCNO>
	<brief_summary>The primary objective study determine baseline yearly response factor ( clinical para clinical ) predict overall disease-free status Month 12 Month 24 , clinical disease-free status subsequent Months 36 48 . The secondary objective : To identify prognostic factor Baseline predict overall disease-free status Month 12 , assess yearly overall disease-free response factor predict overall disease-free status Month 24 ; To evaluate clinical disease-free status ( relapse , Expanded Disability Status Scale [ EDSS ] ) analysis time point Months 12 , 24 , 36 , 48 ; To identify prognostic factor Baseline predict clinical disease-free status Month 12 , assess yearly clinical disease-free response factor predict clinical disease-free status ( relapse , EDSS ) subsequent year Months 24 , 36 , 48 ; To evaluate impact Tysabri analysis time point Months 12 , 24 , 36 , 48 following : annualized relapse rate ( ARR ) , sustain EDSS progression improvement ( 24-week sustain ) ; To evaluate impact Tysabri analysis time point Months 12 , 24 , 36 , 48 following : magnetic resonance image ( MRI ) measure : T2 , T1 , T1 Gadolinium ( Gd ) , brain atrophy ; To evaluate impact Tysabri Month 24 Month 48 follow : optical coherence tomography ( OCT ) , Low High Contrast Visual Acuity Assessment ; To evaluate impact Tysabri analysis time point Months 12 , 24 , 36 , 48 following : cognitive impairment ( Symbol Digit Modalities Test [ SDMT ] ) , capacity work ( Work Productivity Activity Impairment Questionnaire [ WPAI ] ) , quality life ( QoL ) ( Multiple Sclerosis Impact Scale [ MSIS-29 ] )</brief_summary>
	<brief_title>Observational Study Tysabri Early Relapsing-Remitting Multiple Sclerosis Anti-JC Virus Antibody Negative Participants</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Documented diagnosis Relapsing Multiple Sclerosis ( McDonald 2010 Criteria ) . &lt; 3 year disease duration . Must Expanded Disability Status Scale ( EDSS ) score 0 4.0 , inclusive . AntiJCV antibody negative test within 6 month Screening Visit . Must satisfy approve therapeutic indication Tysabri . Must treatmentnaïve diseasemodifying therapy ( DMT ) treat DMT ( include limit Avonex , Betaseron , Rebif , Copaxone , Extavia , Gilenya ) ≤36 month total prior date inform consent . Decision treat Tysabri must precede enrollment . Key Any prior treatment Tysabri . AntiJCV antibody positive timepoint prior Screening Visit . Contraindications treatment Tysabri describe US Prescribing Information . History progressive multifocal leukoencephalopathy ( PML ) opportunistic infection , increase risk infection . History diagnosis Primary Progressive Multiple Sclerosis ( PPM ) and/or Secondary Progressive Multiple Sclerosis ( SPMS ) . Receiving immunomodulatory immunosuppressive therapy . Prior history immunosuppressive use ( mitoxantrone , azathioprine , methotrexate , cyclophosphamide , mycophenolate , cladribine , rituximab ) . Immunocompromised time enrollment . Known active malignancy ( subject cutaneous basal cell carcinoma completely excise prior study entry remain eligible ) . Women breastfeed , pregnant , plan become pregnant ; woman postmenopausal surgically sterile unwilling practice contraception . Inability comply study requirement . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>